This core provides the overall management and administrative support for the Program Project grant, mainly related to the multicenter selective lymphadenectomy trials (MSLT) I and MSLT-II, which are at the heart of the entire grant. The John Wayne Cancer Institute (JWCI) database, which includes data on about 14,000 patients who are not enrolled in the MSLT studies, also operates under Core B and supports studies proposed in Projects I, II, and III. In addition, this core coordinates the collection and management of patient specimens (serum and tumor tissue). Finaly, Core B also provides the support for the overall administration of the Program Project, an important part for the integrity of the grant. To consolidate the core activities around the multicenter clinical trials, in this renewal, we conceived a large, complex core that combines the duties of the past Cores B and C (?Research Support? and ?Administrative Service and Multicenter Trial Operations Center?, respectively) and provides essential support to all projects. This consolidation was possible only due to the strong unity of this grant around the multicenter clinical trials MSLT-I and MSLT-II, around which gravitate all three projects and cores.
the specific aims of Core B are: 1) to fulfill all the duties and responsibilities of a multicenter trials operations center for MSLT-I and MSLT-II, including the MSLT-I and -II databases administration;2) to support the JWCI databse administration;3) to sustain the collection, processing, archiving, and retrieval of serum and tumor tissue specimens from the MSLT and JWCI sites; and 4) to provide administration to the individual projects and cores of the Program Project. In conclusion, this large and complex administrative core concentrates the grant administration, multicenter clinical trial operations, JWCI database administration, and the collection of important specimens supporting aims in all projects of the grant.
The main functions of Core B are to support a) the administration of this Program Project through the years 28 to 32, b) the smooth running of two international multicenter clinical trials, MSLT-I and MSLT-II, c) the administration of the JWCI database (-14,000 patients), and d) to sustain collection and archival of certain specimens from MSLT sites and the JWCI clinic. All projects directly rely on this complex support of Core B.
|Jones, Maris S; Lee, Jihey; Stern, Stacey L et al. (2017) Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes? J Am Coll Surg 225:149-158|
|Faries, Mark B; Thompson, John F; Cochran, Alistair J et al. (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376:2211-2222|
|Ozao-Choy, Junko; Nelson, Daniel W; Hiles, Jason et al. (2017) The prognostic importance of scalp location in primary head and neck melanoma. J Surg Oncol 116:337-343|
|Karakousis, Giorgos; Gimotty, Phyllis A; Bartlett, Edmund K et al. (2017) Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. Ann Surg Oncol 24:952-959|
|Jones, Maris S; Torisu-Itakura, Hitoe; Flaherty, Devin C et al. (2016) Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surg 82:1009-1013|
|Faries, Mark B (2016) Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology. Crit Rev Oncog 21:65-73|
|Marzese, Diego M; Liu, Michelle; Huynh, Jamie L et al. (2015) Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res 28:82-93|
|Wang, Jinhua; Hua, Wei; Huang, Sharon K et al. (2015) RASSF8 regulates progression of cutaneous melanoma through nuclear factor-?b. Oncotarget 6:30165-77|
|Faries, Mark B (2015) From the guest editor: The sentinel node: evolution of the revolution. Introduction. Cancer J 21:1-2|
|Ono, Shigeshi; Oyama, Takashi; Lam, Stella et al. (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053-64|
Showing the most recent 10 out of 256 publications